# EU-1-13-909_public-assessment-report_20140516_20140722_bemfola-epar-public-assessment-report.pdf

EUROPEAN MEDICINES AGENCY
MEDICINES
HEALTH
SCIENCE
26 June 2014
EMA/65507/2013 rev.1
Committee for Medicinal Products for Human Use (CHMP)
Assessment report
Bemfola
International non-proprietary name: Follitropin alfa
Procedure No. EMEA/H/C/002615
Note
Assessment report as adopted by the CHMP with all information of a commercially confidential
nature deleted.
7 Westferry Circus . Canary Wharf . London E14 4HB . United Kingdom
Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7418 8613
E-mail info@ema.europa.eu Website www.ema.europa.eu
An agency of the European Union
Product information
Name of the medicinal product:
Bemfola
Applicant:
Finox Biotech AG
Gärten 71
FL-9496 Balzers
Liechtenstein
Active substance:
rhfsh, follitropin alfa
International Non-proprietary Name:
rhfsh, follitropin alfa
Pharmaco-therapeutic group
(ATC Code):
(G03GA05)
Therapeutic indications:
·
Anovulation (including polycystic ovarian
disease, PCOD) in women who have been
unresponsive to treatment with
clomiphene citrate.
Follitropin alfa
In adult women
· Stimulation of multifollicular
development in patients undergoing
superovulation for assisted reproductive
technologies (ART) such as in vitro
fertilisation (IVF), gamete intra-fallopian
transfer (GIFT) and zygote intra-fallopian
transfer (ZIFT).
.
Bemfola in association with a luteinising
hormone (LH) preparation is
recommended for the stimulation of
follicular development in women with
severe LH and FSH deficiency. In clinical
trials these patients were defined by an
endogenous serum LH level <1.2 IU/l.
In adult men
·
Bemfola is indicated for the stimulation of
spermatogenesis in men who have
congenital or acquired
hypogonadotrophic hypogonadism with
concomitant human Chorionic
Assessment report
EMA/65507/2013 rev. 1
Page 2/76
